However, although patients who were of BRCA1 or BRCA2 mutations did not seem to have an increased risk of adverse effects in the phase I monotherapy trial (Fong et al, 2009), it is plausible that this combination in women with advanced ovarian cancer may yield a higher toxicity profile due to differing disease distribution. This evidence concerns the gene BRCA2 and ovarian cancer.